The Netherlands offers a particularly instructive case study. In 2001, the Amsterdam District Court ruled that ayahuasca does not represent a danger to public health when used within the context of Santo Daime ceremonies, and that religious freedom under Article 9 of the European Convention on Human Rights, the right to freedom of religion, protected its use. The ruling was supported by extensive expert testimony. Among the witnesses was Prof. Charles Kaplan of the University of Maastricht, who testified that ritual ayahuasca use is beneficial for public mental health. Kaplan had also researched the history of LSD therapy in Dutch psychiatry alongside Stephen Snelders, the threads between Bastiaans' era and the present running closer than is often recognised. The ruling was celebrated internationally as a precedent. For almost eighteen years, Santo Daime churches in the Netherlands operated under this protection. Confiscations at customs continued — they were a recurring reality — but criminal charges were consistently dismissed on religious freedom grounds, and the sacrament was returned. In 2018, the Amsterdam Court of Appeal reversed course. The court identified four concrete concerns about unregulated ayahuasca use: intake not performed by medical professionals, dosing difficult to standardise, no systematic aftercare, and storage and transport insufficiently controlled. In 2019, the Dutch Supreme Court confirmed the reversal, ruling that the Opium Act's prohibition takes precedence over religious freedom and that a general assessment suffices — effectively closing the door to case-by-case judicial evaluation. The European Court of Human Rights declined to overrule the Dutch position, holding that the Netherlands has discretion in how it balances these competing rights. What makes the 2018 ruling particularly notable is that the four concerns it identified are regulatory problems — problems that a legal framework could address. They are about safety, screening, standards, and accountability. Instead of creating such a framework, the response was to close the legal door entirely. The Canadian model: proof of concept Canada offers a working alternative. Since 2017, at least six organisations have received legal exemptions to import and use ayahuasca under Section 56 of the Controlled Drugs and Substances Act. The crucial provision: the Canadian minister of health may grant exemptions, on a discretionary, case-by-case basis, not only for medical or scientific purposes, but when this is "otherwise in the public interest." That final ground is deliberately broad — it does not limit exemptions to religious use, but allows the minister to consider any context in which regulated access serves the public good. The first exemption, granted to Céu do Montréal in 2017, was for a religious organisation. But the conditions Health Canada attached are not religion-specific. They are safety standards: qualified leadership, participant screening for health and medication contraindications, a registered supply chain, transport and storage protocols following government guidelines, and safeguards to prevent the brew from being used outside its authorised context. These conditions directly address every concern the Amsterdam Court of Appeal raised in 2018. It is worth stating plainly what makes regulation necessary. Ayahuasca is not risk-free. The brew contains MAO inhibitors that interact dangerously with common medications including antidepressants. Psychological risks are real, particularly for people with a history of psychosis or severe psychiatric conditions. Unqualified facilitators, absent screening, unsafe settings, and the absence of aftercare have caused real harm in unregulated contexts. These are not arguments against ayahuasca. They are arguments against the absence of standards. Precisely because the brew is powerful and not without risk, a grey zone in which no enforceable safety requirements exist serves no one — not participants, not practitioners, and not public health. André van der Braak, professor at VU Amsterdam, examined the Canadian model in a 2020 analysis and noted that the Dutch Opium Act has a structurally similar ministerial exemption system. The critical difference: the Netherlands' grounds for exemption are a fixed, closed list — public health, scientific research, instructional purposes, and cannabis cultivation. There is no open "public interest" ground. Any use that falls outside these categories cannot be regulated, even if the minister would consider it appropriate. Legal scholars have noted that the gap could be closed by broadening the grounds in Article 8 of the Opium Act to include something comparable to the Canadian "public interest" provision. The existing powers in Article 8a already allow the minister to attach detailed conditions to any exemption. The legal infrastructure, in other words, is already in place. What is missing is the ground on which to use it. This is not a new argument. Prof. H.J.B. Sackers at Radboud University argued as early as 2007 that the Opium Act's exemption system should be expanded. His original suggestion was specifically for religious purposes, but the logic applies more broadly. A "public interest" ground would encompass religious, ceremonial, therapeutic, and other contexts without forcing the legislature to define or favour any one of them — and without reopening the politically sensitive question of which practices qualify as genuinely religious. The public interest argument beyond religion The "public interest" framing matters because it is deliberately broader than religious freedom. Three developments make this breadth important. First, the mental health capacity crisis. The dominant clinical model for psychedelic-assisted therapy — developed in university trials — requires two therapists per patient for a full session day of six to eight hours, approximately forty-two hours of therapist involvement per patient including preparation and integration, at a cost of $10,000 to $15,000 per treatment course. In the United States, a shortage of 31,000 mental health workers is projected. The "therapist bottleneck" is not speculative — it is the most significant barrier to access. Ceremonial group settings — the format in which ayahuasca has been used for centuries — offer a fundamentally different model. A 2023 study in Frontiers in Psychiatry (Marseille et al.) compared the cost and capacity of group versus individual psychedelic therapy and found cost reductions of approximately 35–50% and a dramatic increase in the number of patients each therapist can support per year. Second, the therapeutic value of the group itself. Research on "communitas" — the sense of deep connection arising in shared ritual experience — shows significant correlations with lasting improvements in psychological wellbeing. Yalom's classical model of group therapy factors has been applied to psychedelic group settings, with MDMA identified as a "social catalyst" and the group dynamic recognised as an active therapeutic ingredient, not merely a cost-saving mechanism. Third, the urgency created by contemporary trauma. Veterans returning from international missions, the psychological aftermath of the Ukraine conflict across Europe, treatment-resistant PTSD and depression — these represent a growing population for whom conventional treatment has limited efficacy. The Netherlands has its own veterans; the need is not abstract. A legal framework limited to clinical or religious grounds would miss this broader picture. The open "public interest" norm captures all of it — religious practice, ceremonial therapeutic use, mental health capacity relief — without requiring the legislature to enumerate specific applications. There is also a deeper constitutional dimension that has received little attention in Dutch policy debates. Ligthart argues that the right to mental self-determination, grounded in Article 8 EVRM (the right to private life), includes the right to make choices about one's own consciousness. The European Court of Human Rights has held that even the decision to smoke falls within the freedom to make choices about one's own body and health. By analogy, a strict prohibition on substances that alter consciousness requires a proportionality test: the restriction must be necessary in a democratic society. For substances whose health risks are, by the government's own assessment, minimal, that test becomes increasingly difficult to pass. This argument applies not only to ayahuasca but to the broader category of psychedelics, and it operates independently of religious freedom claims. A Dutch historical precedent The Netherlands has historical precedent for allowing psychedelic-assisted treatment when the need was considered pressing. In the 1960s, Prof. Jan Bastiaans at Leiden University began using LSD to treat concentration camp survivors suffering from what was then called KZ-syndrome — severe, treatment-resistant post-traumatic disturbance. Over two decades, he treated approximately three hundred patients, with the government's knowledge. The 1969 documentary Begrijpt u nu waarom ik huil? brought his work to national attention. Bastiaans' methods were later questioned, and his legacy is contested. But the principle he established — that extreme suffering can justify unconventional therapeutic approaches, and that a government can find a way to permit them — remains part of Dutch psychiatric history. Where the weight falls The current legal situation across Europe is characterised by what Fagundes calls "great legal ambiguity." The same preparations that are subject to regulated exemptions in Brazil, the United States, and Canada become criminalised contraband when crossing European borders. Practitioners face prosecution not because the law is clear, but because it is not. In legal terms, this is a failure of legal certainty — the principle that citizens must be able to know, in advance, what the law requires of them. And in the absence of legal clarity, no enforceable safety standards can exist. The academic debate is shifting. Martín Pardo's analysis in Spain, Van der Braak's comparative work in the Netherlands, the growing research literature on the therapeutic value of ceremonial group settings — these point in a consistent direction. In March 2026, Sjors Ligthart of Tilburg University published a detailed analysis in the Nederlands Juristenblad, one of the country's most prominent legal journals, arguing that the position of psychedelics in Dutch drug policy requires fundamental reconsideration. Ligthart documents a pattern of scientific evidence being overruled by political calculation: the government's own advisory body, the CAM, has repeatedly concluded that psychedelics pose minimal public health risk, yet they remain classified alongside heroin and fentanyl on List I of the Opium Act. The 2011 Expert Commission on the Opium Act's classification system concluded that alcohol and tobacco would meet the criteria for List I placement, yet cultural and economic interests keep them off the list entirely. Psychedelics receive no such balancing of benefits against harms. The question is no longer whether regulation could work. Canada has demonstrated that it can. The question is whether European legislatures will act. The Dutch case is particularly instructive because the legal infrastructure is already in place. The Opium Act has a ministerial exemption system. Article 8a provides the power to attach conditions. The Amsterdam Court of Appeal has already identified what those conditions should address. What is missing is a broader ground for exemption that would allow the system to function as its Canadian counterpart already does. Whether the political will exists is a separate question. But the legal logic is sound and the international precedent is growing. On 18 April 2026, the US president signed an executive order directing the FDA to fast-track psychedelic therapies, establishing Right to Try access for patients with life-threatening conditions, and committing federal research funding. European authorities continue to prosecute ayahuasca as drug trafficking, while the United States is accelerating medical and regulatory pathways for related psychedelic compounds. The cost of continued ambiguity — measured in prosecutions, detentions, and the absence of safety standards in a field that urgently needs them — is becoming harder to justify. This article is for informational purposes only and does not constitute legal advice. Laws regarding ayahuasca vary significantly by jurisdiction and change frequently. Anyone considering participation in ayahuasca ceremonies should research the current legal status in their specific location and consult with legal counsel if uncertain. Sources Legal and academic Martín Pardo, A. (2025). "Implicaciones penales de los comportamientos relacionados con la ayahuasca." Revista de Derecho Penal y Criminología, 34(JULIO), UNED. Martín Pardo, A. & Muñoz Sánchez, J. (2019). El estatuto legal de la ayahuasca en España. Tirant lo Blanch. Van der Braak, A. (2020). "Ayahuasca: drug, sacrament of medicijn?" NTKR, 2020/1, pp. 47–71, Uitgeverij Paris. Sackers, H.J.B. (2007). Annotation, NJCM-Bulletin, 32(4), 458–466. Ligthart, S.L.T.J. (2026). "Psychedelica in het Nederlandse drugsbeleid: Aanzet tot een grondige herbezinning." Nederlands Juristenblad, NJB 2026/401, 2026/8, pp. 590–598. Staatscommissie MDMA (2024). MDMA: Voorbij de extase. Van der Plas, A. (2023). Legal Paper on the Status of Ayahuasca Under the Dutch Legal System. ICEERS. Court decisions District Court of Amsterdam, 21 May 2001 (Case 13/067455-99) Hof Amsterdam (Court of Appeal), 28 February 2018 (23/003371-16, ECLI:NL:GHAMS:2018:688) HR 1 October 2019 (ECLI:NL:HR:2019:1456) EHRM (European Court of Human Rights), 6 May 2014, Fränklin-Beentjes and Ceflu-Luz da Floresta v. Netherlands Research Marseille, E. et al. (2023). "Group psychedelic therapy." Frontiers in Psychiatry, 14. Kettner, H. et al. (2021). "Psychedelic Communitas." Frontiers in Pharmacology, 12. Ponomarenko, P. et al. (2023). "Can psychedelics enhance group psychotherapy?" Journal of Psychopharmacology, 37(7). Thomas, G. et al. (2013). "Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada." Current Drug Abuse Reviews, 6(1), 30–42. Historical Snelders, S. (2000). LSD-therapie in Nederland: De experimenteel-psychiatrische benadering van J. Bastiaans, G.W. Arendsen Hein en C.H. van Rhijn. Amsterdam: Candide. Van Bergen, L. (2022). Bevrijd: Het concentratiekampsyndroom en de LSD-behandeling van Jan Bastiaans. Nijmegen: QV Uitgeverij.